Dr. Mohammad F. Asad, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,007
Licensed in Illinois since 2021, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036155397 (first issued 2021; active) -
Internal Medicine Physician
FL license ME115416 · IL license 036155397 (first issued 2021; active) · MI license 4301114239
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Medical Center Peoria, IL
- Carle Health Methodist Hospital Peoria, IL
- Carle Health Proctor Hospital Peoria, IL
- Osf Saint Katharine Medical Center Dixon, IL
- Cgh Medical Center Sterling, IL
Medical groups
- Oncology-Hematology Associates of Central Illinois P C (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,007
- Services billed
- 257,283
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 50,490 | 69 |
| Injection, ferric carboxymaltose, 1 mg | 36,700 | 40 |
| Injection, pembrolizumab, 1 mg | 12,400 | 26 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11,530 | 121 |
| Injection, denosumab, 1 mg | 8,280 | 43 |
| Injection, nivolumab, 1 mg | 7,900 | 12 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,480 | 15 |
| Injection, paclitaxel, 1 mg | 5,765 | 14 |
| Injection, iron sucrose, 1 mg | 4,000 | 11 |
| Injection, aprepitant, 1 mg | 3,510 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Peoria, IL | 119 |
| Acyclovir Other prescribers in Peoria, IL | 118 |
| Anastrozole Other prescribers in Peoria, IL | 118 |
| Dexamethasone Other prescribers in Peoria, IL | 109 |
| Prednisone Other prescribers in Peoria, IL | 105 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Peoria, IL | 90 |
| Ondansetron Hcl Other prescribers in Peoria, IL | 89 |
| Revlimid (lenalidomide) | 78 |
| Olanzapine Other prescribers in Peoria, IL | 77 |
| Hydroxyurea Other prescribers in Peoria, IL | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $388,241 in research payments for these studies, mostly to the institutions running them.
- Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
AbbVie Inc. - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.